New FDA Leadership Changes Priorities But Doesn’t Change Administration Regulations, Panel Discussion Says

Biotech Investing News—

Biotech Investing News reporters this week covered a panel featuring Catalyst’s President, Nancy Bradish Myers.

In the panel, which took place on the first day of the JP Morgan Healthcare conference, at the coinciding Biotech Showcase, Myers discussed how new leaders at FDA are shaping the agency. She underscored that now is the time “for companies to engage the regulatory agency,” the article notes.

The article continues: Myers said “this is a rare time for the agency as it publicly engages with the market like no other time before. She said this is a perfect opportunity for companies to approach the agency and discuss issues with regulatory framework and upcoming guidances. Myers recommended companies to be creative and take a step forward to engage with this FDA, which she said seems willing to expand the interpretation of their own statute.”

Read previous coverage of the January 8th panel, “The impact of new leadership and new initiatives at FDA,” from The Pink Sheet, here. (subscription required).